Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Birth Defects Prevention Act of 1997

This article was originally published in The Tan Sheet

Executive Summary

Birth Defects Prevention Act of 1997: Substitute bill S 419 passes Senate by voice vote June 12 and is referred to the House Commerce Committee. The bill would "provide surveillance, research and services aimed at prevention of birth defects," including "public awareness strategies, such as programs using folic acid vitamin supplements to prevent spina bifida." S 419 calls for the Centers for Disease Control & Prevention to collect and analyze data on birth defects, operate regional research centers and provide public education. The bill allocates $30 mil. for fiscal 1998, $40 mil. for FY 1999 and "such sums as may be necessary" for FYs 2000 and 2001. A House bill identical to the original S 419, which gives CDC less discretion, also is before House Commerce...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel